Kyprolis Helped Patients Live 8.7 Months Longer Without Their Disease Worsening
Results to Form Basis of Regulatory Filings Beginning in 1H 2015

Thousand Oaks, California and South San Francisco, California (Press Release) Amgen (NASDAQ:AMGN) and its sub­sid­i­ary, Onyx Pharma­ceu­ticals, Inc., today announced that a planned interim analysis demon­strated that the Phase 3 clin­i­cal trial ASPIRE (CArfilzomib, Lena­lido­mide, and DexamethaSone versus Lena­lido­mide and Dexamethasone for the treat­ment of PatIents with Relapsed Multiple MyEloma) met its pri­mary end­point of pro­gres­sion-free survival (PFS). Patients treated with Kyprolis® (car­filz­o­mib) for Injection in com­bi­na­tion with Revlimid® (lena­lido­mide) and low-dose dexa­meth­a­sone (KRd) lived sig­nif­i­cantly longer without their disease worsening (median 26.3 months) compared …

• Results show adding LBH589 to bortezomib and dexamethasone significantly improved PFS by 37%, meeting Phase III study primary endpoint[1]
• Median PFS increased by 4 months (12 months in LBH589 arm versus 8 months in placebo arm); effect of LBH589 observed across all patient subgroups[1]
• Most people with multiple myeloma will relapse or become refractory; if approved, LBH589 will be first in its class of anticancer agents available to this population[1]
• Based on these data, US

 …

- 4/12 patients (33%) showed evi­dence of stable disease; 2 patients for more than 130 days
- A clin­i­cally-relevant mean time to next ther­apy of 51 days
- PAT-SM6 specifically targets myeloma tumour cells in vivo and stimulates signifcant immune responses
- All dose levels admin­istered were safe with no adverse events observed
- No evi­dence of immunogenicity; PK analysis showed PAT-SM6 to have a half-life of 7 hrs

Melbourne, Australia (Press Release) - Patrys Limited (ASX: PAB; “the Company”), a clin­i­cal stage bio­tech­nology com­pany, is pleased to announce the final results from …

− Oral Data Presentation to be Featured in “Highlights of ASH” −

New Orleans, LA & Osaka, Japan (Press Release) - Takeda Pharma­ceu­tical Company Limited (TSE:4502) today announced final Phase 1 and pre­lim­i­nary Phase 2 results of a study combining oral inves­ti­ga­tional MLN9708 admin­istered twice a week with lena­lido­mide and dexa­meth­a­sone in patients with newly diag­nosed multiple myeloma (MM). The investigators reported a com­bined com­plete response and very good partial response (CR+VGPR) rate of 76 per­cent (46/62) and a 94 per­cent over­all response rate (ORR; 58/62 ≥ partial response). Stringent com­plete response (sCR) was reached in 75 per­cent of patients …

- Additional Preclinical Data Presented on Ricolinostat in Potential New Drug Combinations and HDAC6 Biomarkers in Multiple Myeloma -

Boston, MA (Press Release) - Acetylon Pharma­ceu­ticals, Inc., the leader in the devel­op­ment of selective histone deacetylase (HDAC) inhibitors for en­hanced thera­peutic out­comes, today announced that positive interim clin­i­cal data from the two proof-of-concept clin­i­cal trials with selective HDAC6 inhibitor, ricolinostat (ACY-1215), were presented at the 55th Annual Meeting of the American Society of Hematology (ASH) in New Orleans, LA. The two trials are the Phase 1b dose escalation portion of …

- Study of LBH589 plus bor­tez­o­mib and dexa­meth­a­sone met pri­mary end­point of extending PFS compared to bor­tez­o­mib plus dexa­meth­a­sone and placebo
- LBH589 has poten­tial to be the first in its class of anticancer agents avail­able to patients with multiple myeloma
- Data will be presented at an upcoming medical congress and discussed with regu­la­tory author­i­ties world­wide

Basel, Switzerland (Press Release) - Novartis today announced that results of a Phase III trial of the in­ves­ti­ga­tional com­­pound LBH589 (panobinostat) in com­bi­na­tion with bor­tez­o­mib and dexa­meth­a­sone, met the pri­mary end­point of sig­nif­i­cantly extending pro­gres­sion-free …

Poma­lido­mide plus low-dose dexa­metha­sone dem­onstrated sig­nif­i­cantly longer median pro­gres­sion-free survival and over­all survival at a median follow-up of 10 months

Boudry, Switzerland (Press Release) - Celgene Inter­na­tional Sàrl, a wholly-owned sub­sid­i­ary of Celgene Corpo­ra­tion (NASDAQ:CELG), today announced that updated results from MM-003, a phase III multi-center, ran­dom­ized open-label study (n=455) of poma­lido­mide (marketed as POMALYST^® in the U.S. and IMNOVID^® in the E.U.) plus low-dose dexa­metha­sone, were published online ahead of print in The Lancet Oncology.

The study compared oral poma­lido­mide plus low-dose dexa­metha­sone with high-dose dexa­metha­sone in patients with refractory or re­lapsed and refractory multiple myeloma who have failed at least two prior thera­pies with both bor­tez­o­mib and lena­lido­mide, ad­min­is­tered alone or in …